Currently out of the existing stock ratings of Tazeen Ahmad, 258 are a BUY (67.36%), 87 are a HOLD (22.72%), 38 are a SELL (9.92%).

Tazeen Ahmad

Work Performance Price Targets & Ratings Chart

Analyst Tazeen Ahmad, currently employed at BAML, carries an average stock price target met ratio of 60.71% that have a potential upside of 35.37% achieved within 182 days.

Tazeen Ahmad’s has documented 738 price targets and ratings displayed on 59 stocks. The coverage is on Healthcare, Industrials sectors.

Most recent stock forecast was given on ASND, Ascendis Pharma AS at 30-Aug-2026.

Wall Street Analyst Tazeen Ahmad

Analyst best performing recommendations are on SRZN (SURROZEN).
The best stock recommendation documented was for SRZN (SURROZEN) at 11/16/2022. The price target of $15 was fulfilled within 2 days with a profit of $3.6 (19.35%) receiving and performance score of 96.77.

Average potential price target upside

of $135.95 (88.07%) on SQZ (SQZ BIOTECHNOLOGIES CO).
of $116.55 (23.6%) on ARGX (ARGENX NV ADR).
of $35.21 (17.24%) on ALNY (ALNYLAM PHARMACEUTICALS).

ACAD ACADIA Pharmaceuticals ALNY Alnylam Pharmaceuticals BNTX BioNTech SE FOLD Amicus Therapeutics FULC Fulcrum Therapeutics GRTX Galera Therapeutics GWPH GW Pharmaceuticals plc INCY yte NBIX Neurocrine Biosciences PRLD Prelude Therapeutics PTCT PTC Therapeutics RARE Ultragenyx RYTM Rhythm Pharmaceuticals SAGE Sage Therapeutic ASND Ascendis Pharma AS CRTX Cortexyme ORPH Orphazyme A/S SRPT Sarepta Therapeutics BCRX BioCryst Pharmaceuticals PRTA Prothena plc SRZN Surrozen TBPH Theravance Biopharma ADCT ADC Therapeutics SA FATE Fate Therapeutics ADMS Adamas Pharmaceuticals AKUS Akouos ARGX argenx NV ADR CLVS Clovis Oncology CYT Cyteir Therapeutics ETN Eaton PLC KALA Kala Pharmaceuticals MCRB Seres Therapeutics PYXS Pyxis Oncology SGEN Seagen SQZ Sqz Biotechnologies Co ZGNX Zogenix ANNX Annexon ARVN Arvinas PRAX Praxis Precision Medicines ACHL Achilles Therapeutics PLC ADR APLS Apellis Pharmaceuticals CERE Cerevel Therapeutics Holdings PHVS Pharvaris BV FDMT 4D Molecular Therapeutics INZY Inozyme Pharma MRUS Merus BV PEPG PepGen Ltd IMMU Immunomedics DNLI Denali Therapeutics OCUL Ocular Therapeutix PRNB Principia Biopharma STRO Sutro Biopharma KALV Kalvista Pharmaceuticals RNA Avidity Biosciences CORT Corcept Therapeutics OR Osisko Gold Ro SG Sweetgreen SRRK Scholar Rock Holding Corp TCP TC PipeLines LP

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Jeffrey Hung (MORGAN STANLEY)

Hold Since 07-Mar-2025

$28

$-1.11 (-3.81%)

Please subscribe to see extended stock data

Yigal Nochomovitz (CITI)

Buy Since 21-Oct-2025

$40

$10.89 (37.41%)

$39

Please subscribe to see extended stock data

David Hoang (DEUTSCHE BANK)

Buy Since 25-Sep-2025

$38

$8.89 (30.54%)

$29

Please subscribe to see extended stock data

Ashwani Verma (UBS)

Buy Since 17-Oct-2023

$49

$19.89 (68.33%)

$40

Please subscribe to see extended stock data

Ami Fadia (NEEDHAM)

Buy Since 28-Feb-2024

$41

$11.89 (40.85%)

$29

Please subscribe to see extended stock data

Show more analysts

Please expand the browser size to see the chart

Which stock is Tazeen Ahmad is most bullish on?

Potential upside of $172.9 has been obtained for ALNY (ALNYLAM PHARMACEUTICALS)

Which stock is Tazeen Ahmad is most reserved on?

Potential downside of $0.89 has been obtained for ACAD (ACADIA PHARMACEUTICALS)

What Year was the first public recommendation made by Tazeen Ahmad?

On 2012